Paul Boyatzis - Valeant Pharmaceuticals Non-Executive Chairman of the Board
Chairman
Mr. Paul Boyatzis, B Bus, ASA, MSDIA, CPA, has served as NonExecutive Chairman of the Board of Ventnor Resources Ltd since September 24, 2010. He has 25 years of experience in the investment and equity markets and knowledge of public companies. He has assisted emerging companies raise funds both locally and from overseas institutional investors. He is a current member of the Australian Institute of Company Directors, the Securities and Derivative Industry Association and a member of the Certified Practising Accountants of Australia. since 2010.
| Tenure | 14 years |
| Professional Marks | CPA |
| Phone | 514-744-6792 |
| Web | http://www.valeant.com |
Valeant Pharmaceuticals Management Efficiency
The company has Return on Asset of 0.69 % which means that on every $100 spent on assets, it made $0.69 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (21.51) %, meaning that it generated no profit with money invested by stockholders. Valeant Pharmaceuticals' management efficiency ratios could be used to measure how well Valeant Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company has 25.27 B in debt with debt to equity (D/E) ratio of 558.6, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Valeant Pharmaceuticals has a current ratio of 1.16, demonstrating that it may not have the ability to pay its financial commitments when the payables are due. Debt can assist Valeant Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Valeant Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Valeant Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Valeant to invest in growth at high rates of return. When we think about Valeant Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 3 records | CHAIRMAN Age | ||
| Reginald Gillard | Perseus Mining Limited | 66 | |
| Roland Kohl | Highway Holdings Limited | 75 | |
| Paul Barber | ServiceNow | 53 | |
Management Performance
| Return On Equity | -21.51 | |||
| Return On Asset | 0.69 |
Valeant Pharmaceuticals Leadership Team
Elected by the shareholders, the Valeant Pharmaceuticals' board of directors comprises two types of representatives: Valeant Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Valeant. The board's role is to monitor Valeant Pharmaceuticals' management team and ensure that shareholders' interests are well served. Valeant Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Valeant Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Ingram, Lead Independent Director | ||
| Sarah Kavanagh, Independent Director | ||
| Pavel Mirovsky, President of Valeant Europe and General Manager of Valeant Europe | ||
| William Humphries, Executive Vice President Company Group Chairman, Dermatology | ||
| Bruce Maluish, Managing Director, Executive Director | ||
| Norma Provencio, Independent Director | ||
| Richard DeSchutter, Independent Director | ||
| Anders Lonner, Director | ||
| Robert Hale, Director | ||
| Louis Yu, Chief Quality Officer, Global Quality | ||
| Howard Schiller, Interim CEO and Director | ||
| Paul Herendeen, CFO, Executive Vice President - Finance | ||
| Peter Pawlowitsch, Non-Executive Director | ||
| Amy Wechsler, Independent Director | ||
| Colleen Goggins, Independent Director | ||
| Robert Power, Independent Director | ||
| Mason Morfit, Independent Director | ||
| Sherri Wilkin, Chief Creative Officer | ||
| Robert Rosiello, CFO and Executive VP | ||
| Theo MelasKyriazi, Independent Director | ||
| Argeris Karabelas, Independent Director | ||
| William Ackman, Director | ||
| Fredric Eshelman, Independent Director | ||
| Laurie Little, Vice President - Investor Relations | ||
| Christina Ackermann, Executive Vice President General Counsel | ||
| Katharine Stevenson, Independent Director | ||
| Paul Boyatzis, Non-Executive Chairman of the Board | ||
| Ronald Farmer, Independent Director | ||
| Thomas Ross, Independent Director | ||
| Laizer Kornwasser, Executive VP and Company Group Chairman | ||
| Joseph Papa, Chairman of the Board, CEO | ||
| Ari Kellen, Executive VP and Company Group Chairman | ||
| John Geary, Company Secretary | ||
| Elif McDonald, Director, Investor Relations | ||
| Robert ChaiOnn, Executive Vice President General Counsel and Chief Legal Officer, Head of Corporate and Business Development, Director | ||
| John Paulson, Independent Director | ||
| Michael Pearson, Chairman, CEO and Director(Leave of absence) | ||
| Stephen Fraidin, Independent Director | ||
| Thomas Appio, Executive Vice President and Presidentident - Asia Pacific | ||
| Brian Stolz, Executive Vice President - Administration, Chief Human Capital Officer | ||
| Anne Whitaker, Executive Vice President | ||
| Russel Robertson, Independent Director |
Valeant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Valeant Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -21.51 | |||
| Return On Asset | 0.69 | |||
| Profit Margin | (10.65) % | |||
| Operating Margin | 5.01 % | |||
| Current Valuation | 32.38 B | |||
| Shares Outstanding | 349.3 M | |||
| Shares Owned By Insiders | 0.30 % | |||
| Shares Owned By Institutions | 51.10 % | |||
| Number Of Shares Shorted | 14.62 M | |||
| Price To Earning | 3.43 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Valeant Stock
If you are still planning to invest in Valeant Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Valeant Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |